SCHEMBL4066706

SCHEMBL4066706

CCOC(=O)C1Oc2ccc(CC(C)NCC(=O)OC(C)(C)C)cc2O1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.35
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
ADRB2 P07550 4/20 0.34
ADRB1 P08588 3/20 0.34
ADRB3 P13945 3/20 0.34
ADORA2A P29274 2/20 0.33
ADORA1 P30542 1/20 0.33
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 2/20 0.33
ADRA1D P25100 3/20 0.33
ADRA1A P35348 3/20 0.33
ADRA1B P35368 3/20 0.33
PPARG P37231 1/20 0.32
ABCB1 P08183 1/20 0.32
CNR2 P34972 1/20 0.32
POLB P06746 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4068938 0.90 ALDH1A1 (0.39) KMT2ACYP4F2CYP4A11ADRB2ADRB1
SCHEMBL4065532 0.88 ADRA1D (0.35) ADRB2ADRB1ADRB3ADRA1DADRA1A
SCHEMBL4063474 0.86 ACACB (0.36) CYP4F2CYP4A11PPARG
SCHEMBL4066701 0.79 CYP4F2 (0.35) KMT2ACYP4F2CYP4A11ADORA2AADORA1
SCHEMBL14491744 0.79 SYK (0.41) CYP4F2CYP4A11ALDH1A1PPARG
SCHEMBL4068936 0.78 CYP4F2 (0.34) CYP4F2CYP4A11ADORA2AADORA1ALDH1A1
SCHEMBL4058031 0.78 SIGMAR1 (0.38) ADRB2ADRB1ADRB3ALDH1A1KDM4E
SCHEMBL13748626 0.76 CYP4F2 (0.34) CYP4F2CYP4A11ADORA2AADORA1ALDH1A1
SCHEMBL13748914 0.72 ACE (0.39) PPARG
SCHEMBL10593205 0.72 RXRA (0.40) KMT2AADRB2ADRB1ADRB3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569676-B2 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2009-08-04 US disclosed
EP-1498415-B1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS GMBH (DE) 2007-06-27 EP disclosed
US-7060847-B2 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2006-06-13 US disclosed
US-20050153439-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs GHOSHAL MITALI (US) 2005-07-14 US disclosed
US-20050014210-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS CORPORATION 2005-01-20 US disclosed
EP-1498415-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs Roche Diagnostics GmbH (DE) 2005-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014210-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs DRD3, SLC6A3, DRD2 KMT2A 1360/4885CYP4F2 1421/4885CYP4A11 1014/4885
US-20050153439-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs DRD3, SLC6A3, DRD2 KMT2A 1360/4885CYP4F2 1421/4885CYP4A11 1014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.